Business Model

The IGIA team are experienced drug development professionals. Lois Rosenberger, PhD is the President and owner of LBR Regulatory-Clinical Consulting Services (LBR) and Acting CEO of IGIA Pharmaceutics. LBR is a niche Contract Research Organization (CRO) that will be used by IGIA Pharmaceuticals to administer the Phase 2 drug development program for dasatinib.

This innovative business model has the advantages of using the expertise and successful track record of senior level professionals. Being a niche CRO LBR will develop dasatinib as a priority and can provide cost effective services.

Investment Opportunity

IGIA is actively raising funds and inviting investors to participate in this exciting product development to impact the lives of children.

To learn about our business projection, investors’ return on investment, and scientific details, please contact us.